Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 5/20 | 0.67 |
| ▸ | EGFR | P00533 | 11/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.66 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.64 |
| ▸ | GAK | O14976 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163512 | 0.91 | EGFR (0.70) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2163737 | 0.90 | EGFR (0.66) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2163635 | 0.89 | FBP1 (0.63) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2165397 | 0.88 | EGFR (0.60) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2164238 | 0.87 | FBP1 (0.67) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL12963484 | 0.86 | FBP1 (0.91) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2163631 | 0.85 | EGFR (0.55) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2164600 | 0.84 | EGFR (0.66) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2164632 | 0.83 | EGFR (0.51) | FBP1EGFRERBB2ERBB4KDR | |
| SCHEMBL2163467 | 0.83 | PIM1 (0.56) | FBP1EGFRERBB2ERBB4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | claimed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | claimed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | claimed |
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | disclosed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | disclosed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | KDR, FLT1, FLT4 | FBP1 3619/4885EGFR 8/4885ERBB2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.